Model the cost-to-value path of your drug asset.

AssetLens estimates development costs, commercial potential, and NPV across go-alone and outlicensing scenarios.

Integrate Now

AssetLens estimates development costs, commercial potential, and NPV across go-alone and outlicensing scenarios.

Integrate Now

Trusted by Industry Leaders:

Know what your asset is worth before you raise, license, or invest

Integrate Now

4 decision-ready report sections

Revenue. Deal terms. Costs. NPV.

Each report turns fragmented clinical and market signals into the four blocks biotech teams need before fundraising, licensing, or portfolio decisions.

Clinical + commercial landscape

Business context

AssetLens connects active trials, approved therapies, pipeline competitors, sponsors, mechanisms of action, routes of administration, unmet needs, and deal benchmarks.

10+ key investor questions answered

Before the meeting happens

Market size, patient population, competitors, active trials, expected price, development cost, licensing benchmarks, milestones, royalties, revenue forecast, and NPV.

Asset + indication

Input only what matters

User enters a drug asset and disease area – AssetLens builds the commercial logic around that exact pair.

4 decision-ready report sections

Revenue. Deal terms. Costs. NPV.

Each report turns fragmented clinical and market signals into the four blocks biotech teams need before fundraising, licensing, or portfolio decisions.

Clinical + commercial landscape

Business context

AssetLens connects active trials, approved therapies, pipeline competitors, sponsors, mechanisms of action, routes of administration, unmet needs, and deal benchmarks.

10+ key investor questions answered

Before the meeting happens

Market size, patient population, competitors, active trials, expected price, development cost, licensing benchmarks, milestones, royalties, revenue forecast, and NPV.